BioMedNewsBreaks

MondayApr 13, 2026 11:28 am

BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company advancing cancer treatments, announced preliminary results from a clinical trial evaluating its proprietary compound LB-100 in combination with dostarlimab at the 2026 Society of Gynecologic Oncology conference in San Juan, Puerto Rico. Interim data from 20 evaluable patients showed a 40% disease control rate and encouraging survival trends with an acceptable safety profile, supporting continued enrollment of an expanded cohort as the company investigates the combination’s potential to enhance immunotherapy response in ovarian clear cell carcinoma. To view the full press release, visit https://ibn.fm/alcex About LIXTE Biotechnology Holdings, Inc. LIXTE Biotechnology Holdings, Inc. is a clinical-stage…

Continue Reading

MondayApr 13, 2026 9:40 am

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Develops Intox Collect(TM) to Scale AI Voice-Based Intoxication Detection

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) a biotechnology company focused on AI-driven voice analytics for intoxication detection, announced the completion of its Intox Collect(TM) technology, enabling rapid scaling of data collection and analysis across a wide range of substances using voice and facial recognition. The platform enhances the company’s ability to train its AI model, which leverages more than 50 million data points to predict drug and alcohol intoxication through voice with high accuracy, while supporting expansion into regulated industries such as…

Continue Reading

MondayApr 13, 2026 9:30 am

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Doses First Patient in Phase IIa Trial of Concussion Treatment

Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company focused on brain-targeted therapeutics, announced that the first patient has been dosed in its Phase IIa clinical trial evaluating ONP-002 for concussion and mild traumatic brain injury at Mackay Hospital in Australia, shortly after site activation on March 31, 2026. The milestone follows regulatory approval and highlights progress in advancing a first-in-class intranasal neurosteroid designed to address underlying brain injury mechanisms, as the company expands trial sites and targets a large unmet need in a condition with no FDA-approved pharmacological treatments. To view the full press release, visit https://ibn.fm/85CHs About Oragenics, Inc.…

Continue Reading

FridayApr 10, 2026 9:20 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured In AINewsWire Editorial On AI-Driven Pharma Manufacturing

Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in an editorial published by AINewsWire, part of the Dynamic Brand Portfolio at IBN (InvestorBrandNetwork), highlighting the growing role of artificial intelligence in pharmaceutical manufacturing. The editorial underscores a sector-wide shift toward integrating AI directly into production workflows as a continuous compliance layer, enabling real-time monitoring, validation and optimization of processes to meet evolving Good Manufacturing Practice requirements, while positioning companies like Oncotelic at the intersection of biotechnology and advanced digital systems driving scalable efficiency and long-term cost advantages. To view the full press release, visit https://ibn.fm/S3jjv About Oncotelic Therapeutics Oncotelic Therapeutics, Inc. is…

Continue Reading

FridayApr 10, 2026 9:10 am

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Closes $10 Million Offering To Fund Phase 3 Milestones Through 2027

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease, announced the closing of an underwritten public offering raising approximately $10 million in gross proceeds. Combined with existing cash and a recent $1.5 million investment from Board Chair Michael Hoffman, the financing is expected to extend the company’s cash runway through Q2 2027, supporting operations through a key six-month symptomatic data readout from its Phase 3 Alzheimer’s trial and the anticipated New Drug Application submission to the U.S. Food and Drug Administration, while advancing ongoing clinical studies and regulatory…

Continue Reading

ThursdayApr 09, 2026 12:53 pm

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured In Editorial On AI-Driven Transformation of Pharmaceutical Manufacturing 

Oncotelic Therapeutics (OTCQB: OTLC) is highlighted in an AINewsWire editorial examining the growing role of artificial intelligence in pharmaceutical manufacturing, where companies are integrating AI into workflows to enable continuous compliance with evolving GMP standards. The article notes that AI-powered systems are increasingly replacing manual, audit-based approaches with real-time monitoring and data-driven validation, positioning Oncotelic within a broader industry shift toward intelligent, automated production environments designed to enhance data integrity, reduce human error and improve operational efficiency. To view the full press release, visit https://ibn.fm/hPPpd About Oncotelic Therapeutics Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The Company’s mission is to address high-unmet-need cancers…

Continue Reading

WednesdayApr 08, 2026 12:18 pm

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in AINewsWire Editorial on AI-Driven Pharma Compliance 

Oncotelic Therapeutics (OTCQB: OTLC) has been featured in an editorial published by AINewsWire, part of the Dynamic Brand Portfolio@IBN, highlighting the growing role of artificial intelligence in transforming pharmaceutical manufacturing and regulatory compliance. The article outlines a shift from traditional audit-based systems to real-time, AI-driven monitoring that continuously validates and optimizes production processes in alignment with evolving Good Manufacturing Practice standards, positioning companies like Oncotelic at the intersection of life sciences and advanced digital technologies. To view the full press release, visit https://ibn.fm/xduGW About Oncotelic Therapeutics Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The Company’s mission is to address high-unmet-need cancers and rare pediatric indications with…

Continue Reading

WednesdayApr 08, 2026 10:20 am

BioMedNewsBreaks – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Engages IBN to Support Corporate Communications Strategy

Cardio Diagnostics Holdings (NASDAQ: CDIO), a precision cardiovascular medicine company leveraging epigenetics, genetics and artificial intelligence, has engaged IBN to support its corporate communications strategy as it advances blood-based solutions for the prevention and detection of cardiovascular disease. The company develops and commercializes clinical tests and data platforms that integrate molecular biomarkers with AI to generate patient-specific insights, including Epi+Gen CHD(TM), a prescription-only test for assessing three-year coronary heart disease risk, PrecisionCHD(TM) for detection and management, HeartRisk(TM) for population-level intelligence and CardioInnovate360(TM) to support cardiovascular therapy development. To view the full press release, visit https://ibn.fm/hFqWS About Cardio Diagnostics Cardio Diagnostics is…

Continue Reading

TuesdayApr 07, 2026 9:55 am

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Files for Rare Pediatric Disease Designation for Measles Drug Candidate

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antivirals, announced it has filed an application with the U.S. FDA for Rare Pediatric Disease Drug designation for NV-387 as a treatment for measles. The application, which follows a previously submitted orphan drug designation filing, could make the company eligible for a Priority Review Voucher upon approval, supporting regulatory advancement of NV-387 as a potential treatment in a market where no approved measles therapies currently exist. To view the full press release, visit https://ibn.fm/h9IB4 ABOUT NANOVIRICIDES NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a clinical stage company that is creating special…

Continue Reading

MondayApr 06, 2026 9:20 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Labeling Feedback for Preservative-Free Ketamine Application

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has received a letter from the FDA Office of Generic Drugs indicating only minor formatting comments on the proposed label for its preservative-free ketamine product, with a final label submission expected this month and potential approval of its Abbreviated New Drug Application anticipated in Summer 2026 pending final review. The company noted the product could help expand U.S. ketamine supply amid reported shortages and aligns with federal efforts to re-shore critical drug manufacturing, while NRx also continues advancing a Fast Track-designated New Drug Application to evaluate intravenous ketamine for severe depression with suicidal ideation. To…

Continue Reading